Peptides vs. Steroids: Which Builds More Muscle?

What's Stronger?

For sheer mass and strength accrual, traditional anabolic-androgenic steroids (AAS) win. And it's not close. In a 1996 randomized trial in the New England Journal of Medicine, healthy men who got 600 mg of testosterone enanthate a week for 10 weeks while lifting weights gained about 6.1 kg of fat-free mass, and their bench press rose about 22 kg. As of October 2026, no published trial has measured muscle or strength in people who train while using ipamorelin, CJC-1295 or any other growth hormone peptide.

The more useful question is why the gap exists, and the answer is mechanism. Steroids act on muscle directly. The peptides in this comparison act on the pituitary gland and rely on a chain of hormones to reach muscle at all. That difference explains both the size of the effect and the side effects.

The Sledgehammer vs. The Scalpel: A Tale of Two Receptors

It all comes down to how each one sends the muscle-building signal.

How Steroids Work

Anabolic steroids like testosterone, Dianabol, or trenbolone are lipids. They can pass right through the cell membrane and bind to the androgen receptor (AR) inside the cell. This activated steroid-receptor complex then travels into the cell nucleus, where it latches directly onto DNA at specific sites called androgen response elements. Think of it as a key going directly into the ignition of the machinery that controls muscle protein synthesis.

The result is a direct, system-wide command to grow. In a 2003 study, 20 weeks of 300 or 600 mg of testosterone a week increased satellite cells (muscle stem cells that add nuclei to growing fibers) along with fiber size. Because the androgen receptor sits in many tissues, the downsides are body-wide too. Outside testosterone shuts down the body's own production (HPTA shutdown), and a 2014 review in Fertility and Sterility describes low testosterone after use that depends on the dose and how long steroids were taken.

How Peptides Work

Most of the peptides discussed for anabolism are growth hormone secretagogues. This includes GHRHs (like Mod GRF 1-29 or CJC-1295) and GHRPs (like ipamorelin or GHRP-6). Unlike steroids, these peptides can't enter the cell. They work from the outside.

They bind to specific receptors on the surface of pituitary cells (the GHRH receptor and the ghrelin receptor, respectively). This is like ringing the doorbell, not kicking in the door. This signal tells the pituitary to produce and release a pulse of endogenous growth hormone (GH). Your own body makes the hormone; the peptide is just the messenger that places the order. That GH then travels to the liver, which in turn produces IGF-1. IGF-1 is thought to carry much of the anabolic effect, mainly by raising protein synthesis.

The pituitary keeps its brakes on. A 2018 review notes that GH released by secretagogues stays pulsed and subject to negative feedback, which may keep levels from climbing very high. Even CJC-1295 with DAC, which lasts about a week, doesn't cause the constant "GH bleed" often described online. In a 2006 study of healthy men, GH pulses kept their normal frequency and size, while trough GH rose about 7.5-fold and IGF-1 about 45%.

GH also acts differently on tissue. In a 2010 study, two weeks of injected GH in healthy young adults raised collagen synthesis in tendon and muscle without changing synthesis of the contractile proteins that make fibers bigger. Steroids are a direct command. Peptides are a request that goes through a multi-step chain of command, and its clearest effect may be on connective tissue. The exception here is IGF-1 LR3, which attempts to bypass the pituitary and liver. As of October 2026 it has no published human data (we rate it preliminary), and low blood sugar is the risk users report most.

Apples to Oranges: A Head-to-Head Breakdown

Comparing the two directly is tough because they do different things at different scales. Here's how it stacks up for a strength athlete, with the evidence type noted.

MK-677 is an oral non-peptide drug that acts on the same receptor as ipamorelin. In a two-year trial in 65 healthy adults aged 60 to 81, it added about 1.1 kg of fat-free mass at one year versus a 0.5 kg loss on placebo, with no change in strength and a rise in fasting glucose. Injected GH itself added about 2.1 kg of lean mass in fit young adults without improving strength, according to a 2008 review.

Support for the repair peptides is thinner than their reputation. A 2025 systematic review of BPC-157 found that 35 of 36 eligible studies were preclinical. TB-500 is sold as thymosin beta-4, but it's a seven-amino-acid fragment of that protein, and FDA says it has found no human exposure data for the fragment.

The legal row needs a date. As of October 2026, FDA's 2026 warning letters to peptide sellers (March 31 and August 24) say a "research use only" label doesn't stop products from being treated as unapproved new drugs when the seller makes drug claims or sells bacteriostatic water for reconstitution. Australia's TGA issued a similar safety alert in April 2026, naming BPC-157, TB-500 and CJC-1295. Our page on the legal landscape for performance-enhancing substances covers the details.

The Stacking Strategy: Why Not Use Both?

Since steroids and peptides work on different, non-competing pathways, many physique athletes use them together. No trial has tested the combination, so what follows is community practice and reasoning from mechanism.

As users describe it, testosterone provides the direct muscle-building signal via the androgen receptor. This is the base for hypertrophy (making existing muscle cells bigger). A GHRH/GHRP stack like CJC-1295 without DAC and ipamorelin is added on top. Vendor guidance describes two to three doses a day to create separate GH pulses; many forum users report one bedtime dose of each, often 100-300 mcg. Users expect it to add things the testosterone alone can't:

1. Enhanced Fat Loss: GH is lipolytic, and users hope it keeps them leaner while they grow. The MK-677 trial found no drop in fat mass, though.
2. Improved Recovery & Tissue Health: GH raised tendon collagen synthesis in the 2010 study, and joints and tendons can take a beating during heavy steroid cycles. Whether secretagogues protect them hasn't been tested.
3. Potential for Hyperplasia: The high levels of IGF-1 may stimulate satellite cells to a degree that creates new muscle fibers, not just bigger ones. The evidence for this in humans is still theoretical.

Adding a secretagogue doesn't offset steroid risks. Testosterone suppression still happens, and the GH side can raise blood glucose.

What We Still Don't Know

Nobody has run a trial putting a peptide against a steroid. The steroid side has randomized human trials; the peptide side has hormone measurements and a few outcome trials of related compounds, plus animal studies and user reports. Our overview of the growth hormone pathway explains each step between a secretagogue and its effect on tissue.

No one knows whether GH secretagogues add measurable muscle in trained people, or whether they change results when added to steroids. Long-term safety of daily use is unstudied too; our page on long-term effects of peptide use covers what little is known. For injuries, BPC-157 is the peptide lifters mention most, but as of October 2026 no controlled human trial has published results for injury healing.

Anyone who tells you that peptides are a 'safe alternative to steroids' is misinformed. They have their own risks, and gray-market vials add doubt about what's in them. Anyone who tells you that a peptide cycle will give you steroid-like results has no trial to point to. More mechanism comparisons are collected in how peptides work.